CTOs on the Move

Vitara Biomedical

www.vitara.com

 
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.vitara.com
  • 2400, Market Street
    Philadelphia, PA USA 19103
  • Phone: 267.518.6300

Executives

Name Title Contact Details

Similar Companies

Dynarex Corporation

Dynarex Corporation is a Orangeburg, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Enalare Therapeutics

Enalare Therapeutics Inc. is a privately owned clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients suffering from acute respiratory conditions.

Recor Medical

The RADIANCE-HTN Clinical study is a randomized, controlled study to evaluate the Paradise Renal Denervation System intended to treat high blood pressure. The study will be in up to 40 hospitals in 5 countries (US, France, Germany, The Netherlands, UK...

Shoppers Drug Mart

Built on a foundation of professional expertise and personal service, Shoppers Drug Mart has been meeting Canadians` health care needs for 50 years. What was once a small pharmacy in Toronto has grown into an organization of over 1,200 stores from coast to coast, becoming an indelible part of the lives of Canadians, young and old. Yet despite our growth, we have never forgotten our origins. We have always remained true to our belief that the personal satisfaction of each and every customer is at the root of our success - and it can only be ensured by the commitment of people who realize that success is built one customer at a time.

Theseus Pharmaceuticals

Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus` lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).